Clinical trial
A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
NCT07114601 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 6, 2025
- Completion date
- April 30, 2035
- Enrollment
- 421 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.
breast neoplasms, colorectal neoplasms, endometrial neoplasms, esophageal neoplasms, neoplasm metastasis, prostate neoplasm, stomach neoplasms